Organ transplant is an effective treatment for end-stage organ failure. For women, restoration of organ function can restore fertility and the ability to successfully carry a pregnancy. Posttransplant pregnancies have been reported among recipients of all types of solid organ transplants via case and center reports plus registry data. Stable graft function is dependent on prevention of rejection, currently accomplished by using maintenance immunosuppressant medications, to which the fetus is exposed in utero. Common among neonatal outcomes in transplant recipients are preterm and low-birth-weight infants. Emotional, nutritional, and immunologic benefits of breastfeeding have been well-documented and could be valuable for these newborns. Concern must be directed at the effects of the child's exposure to immunosuppressive agents excreted into the breast milk. Breastfeeding could be considered in transplant recipients if it can be shown that the level of exposure does not result in risks to the newborn, immediately and throughout childhood. Despite concerns of health care professionals, some recipients have chosen to breastfeed. Breastfeeding after transplant must be approached with consideration of many issues, and the potential risks require further study. This review focuses on benefits of breastfeeding, common immunosuppressive agents used in organ transplant recipients, a summary of the reports of women who have breastfed their infants while on immunosuppressive therapy and the published studies on breastfeeding and immunosuppressive agents. Recommendations are provided to guide health care professionals to help mothers receiving immunosuppressive agents to make informed choices about breastfeeding their infants.
Get full access to this article
View all access options for this article.
References
1.
American Academy of Pediatrics, Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics.1994;93:776–889.
2.
MeierPPBrownLP. State of the science. Breastfeeding for mothers and low birth weight infants. Nurs Clin North Am.1996;31(2):351–365.
3.
CunninghamAJellifeDJellifeE. Breast-feeding and health in the 1980s: A global epidemiological review. J Pediatr.1991;118(5):659–666.
4.
BooNYLyeMS. The role of expressed breastmilk and continuous positive airway pressure as predictors of survival in extremely low birth weight infants. J Trop Pediatr.2000;46(1): 15–20.
5.
HaganRBenningerHCampbellC. Breastfeeding and the very low birthweight (VLBW) infant [abstract]. Pediatr Res.1996;39(4S):217.
6.
LucasAColeT. Breast milk and neonatal necrotising entero-colitis. Lancet.1990;336(8730):1519–1523.
7.
LucasABrookeOMorleyR. Early diet of preterm infants and development of allergic or atopic disease: Randomised prospective study. BMJ.1990;300(6728):837–840.
8.
LucasAMorleyRColeT. Breast milk and subsequent intelligence quotient in children born preterm. Lancet.1992;339(8788):261–264.
9.
LucasAMorleyRColeTGoreSM. A randomized multicenter study of human milk versus formula and later development in preterm infants. Arch Dis Child Fetal Neonatal Ed.1994;70:141.
10.
MorrisSSGrantham-McGregorSLiraP. Effect of breastfeeding and morbidity on the development of low birth*-weight term babies in Brazil. Acta Paediatr.1999;88(10): 1101–1106.
11.
VavyRBirchDBirchE. Effect of dietary omega-3 fatty acids on retinal function of very-low-birth-weight neonates. Pediatr Res.1990;28(5):485–492.
12.
UraizeeEFGrossS. Improved feeding tolerance and reduced incidence of sepsis in sick very low birth weight infants fed maternal milk. Pediatr Res.1989;25:298A.
13.
RaoMHedigerMLevineR. Effect of breastfeeding on the cognitive function of infants born small for gestational age. Acta Paediatr.2002;91(3):267–274.
14.
MathurNDwarkadasASharmaV. Anti-infective factors in preterm human colostrum. Acta Paediatr Scand.1990;79:1039–1044.
15.
GroërMWalkerW. What is the role of preterm breast milk supplementation in the host defenses of preterm infants? Science vs. fiction. Adv Pediatr.1996;43:335–358.
16.
FrenchASoldinSSoldinO. Milk transfer and neonatal safety of tacrolimus. Ann Pharmacother.2003;37(6):815–818.
17.
BehrensOKohlhawKGünterH. Detection of cyclosporin A in breast milk—is breast-feeding contraindicated?Geburtshilfe Frauenheilkd.1989;49:207–209.
18.
FlechnerSKatzARogersA. The presence of cyclosporine in body tissues and fluids during pregnancy. Am J Kidney Dis.1985;5:60–63.
19.
BryanDHawkesJGibsonR. Interleukin-12 in human milk. Pediatr Res.1999;45(6):858–859.
20.
HamoshM. Bioactive factors in human milk. Pediatr Clin North Am.2001;48(1):69–86.
21.
ButsJ. Bioactive factors in milk. Arch Pediatr.1998;5(3):298–306.
22.
EllisLMastroAPiccianoM. Do milk-borne cytokines and hormones influence neonatal immune cell function?J Nutr.1997;127(suppl):985–988.
23.
ChowanadisaiWLönnerdalB. Alpha 1-antitrypsin and antichymotrypsin in human milk: Origin, concentrations, and stability. Am J Clin Nutr.2002;76:828–833.
24.
DavidsonLALönnerdalB. Fecal alpha 1-antitrypsin in breast-fed infants is derived from human milk and is not indicative of enteric protein loss. Acta Paediatr Scan.1990;70:137–141.
25.
HansonLWinbergJ. Breast-milk and defense against infection in the newborn. Arch Dis Child.1972;47:845–848.
26.
LindhE. Increased resistance of immunoglobulin dimmers to proteolytic degradation after binding of secretory component. J Immunol.1985;113:284–288.
27.
AgunodMYamaguchiNLopezRLuhbyALGlassJerzy GB. Correlative study of hydrochloric acid, pepsin and intrinsic factor secretion in newborns and infants. Am J Dig Dis.1969;14:400–414.
28.
LindquistSHernellO. Lipid digestion and absorption in early life: An update. Curr Opin Clin Nutr Metab Care.2010; 13:214–230.
29.
KayeJL. Review of paediatric gastrointestinal physiology data relevant to oral drug delivery. Int J Clin Pharm.2011; 33:20–24.
RitschelWAKearnsGL. Handbook of Basic Pharmacokinetics… Including Clinical Applications.7th ed.Washington, DC: American Pharmaceutical Association; 1999.
32.
RayburnW. Glucocorticoid therapy for rheumatic diseases: Maternal, fetal, and breast-feeding considerations. Am J Reprod Immunol.1992;28(3–4):138–140.
33.
BenediktssonRCalderAAEdwardsCRWSecklJR. Placental IIβ-hydroxysteroid dehydrogenase: A key regulator of fetal glucocorticoid exposure. Clin Endocrinol.1997;46: 161–166.
34.
Park-WyllieLMazzottaPPastuszakA. Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. Teratology.2000;62:385–392.
35.
RayburnW. Glucocorticoid therapy for rheumatic diseases: Maternal, fetal, and breast-feeding considerations. Am J Reprod Immunol.1992;28(3–4):138–140.
36.
OstensenMHusbyG. Antirheumatic drug treatment during pregnancy and lactation. Scand J Rheumatol.1985;14:1–7.
37.
GreenbergerPA. Pharmacokinetics of prednisolone transfer to breast milk. Clin Pharmacol Ther.1993;53:324–328.
38.
MateraL. Endocrine, paracrine, and autocrine actions of pro-lactin on immune cells. Life Sci.1996;59(8):599–614.
39.
BramhamKChusneyGLeeJWardleAPNelson-PiercyCLightstoneL. Tacrolimus and breastfeeding: How safe is it?J Am Soc Nephrol.2011;22:206.
40.
ScalesDGrantonJ. The transplant patient. In: HallJBSchmidtGAWoodLDH, eds. Principles of Critical Care.3rd ed.Cleveland, OH: McGraw-Hill Professional; 2005.
41.
SauAClarkesSBassJ. Azathioprine and breastfeeding—is it safe?Br J Obstet Gynaecol.2007;114(4):498–501.
42.
KrenskyAVincentiFBennettW. Immunosuppressants, tolerogens, and immunostimulants. In: BruntonLLLazoJSParkerKL, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics.11th ed.Cleveland, OH: McGraw-Hill Professional; 2005.
National Transplantation Pregnancy Registry. 2011 Annual Report.Thomas Jefferson University: June 2012. http://www.jefferson.edu/ntpr. Accessed March 18, 2013.
45.
VenkataramananRKoneruBWangC. Cyclosporine and its metabolites in mother and baby. Transplantation.1988;46:468–469.
46.
WinklerMNiesertSRingeB. Successful pregnancy in a patient after liver transplantation maintained on FK 506. Transplantation.1993;56(6):1589–1590.
47.
Di PaoloSSchenaAMorroneL. Immunologic evaluation during the first year of life of infants born to cyclosporine-treated female kidney transplant recipients: Analysis of lymphocyte subpopulations and immunoglobulin serum levels. Transplantation.2000;69:2049–2054.
48.
BaarsmaRKampsW. Immunological responses in an infant after cyclosporine A exposure during pregnancy. Eur J Pediatr.1993;152:476–477.
49.
TakahashiNNishidaHHoshiJ. Severe B cell depletion in newborns from renal transplant mothers taking immunosuppressive agents. Transplantation.1994;57:1617–1621.
50.
GoldsteinLDolinskyGGreenbergR. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol.2007;79:696–701.
51.
StanleyCGottliebRZagerR. Developmental well-being in offspring of women receiving cyclosporine post-renal transplant. Transplant Proc.1999;31:241–242.
52.
LavelanetAFCosciaLAMoritzMJArmentiVT. Long-term follow-up in the offspring of Sandimmune treated female kidney recipients. Am J Transplant.2006;82(1):164.
53.
De BoerNJarbandhanSDe GraafP. Azathioprine use during pregnancy: Unexpected intrauterine exposure to metabolites. Am J Gastroenterol.2006;101:1390–1392.
54.
ClearyBKällénB. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol.2009;85:647–654.
55.
LeRayCCoulombAElefantE. Mycophenolate mofetil in pregnancy after renal transplantation: A case of major fetal malformations. Obstet Gynecol.2004;103:1091–1094.
56.
PérgolaPKancharlaARileyD. Kidney transplantation during the first trimester of pregnancy: Immunosuppression with mycophenolate mofetil, tacrolimus, and prednisone. Transplantation.2001;71:994–997.
57.
SifontisNCosciaLConstantinescuSLavelanetAMoritzMArmentiV. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation.2006;82:1698–1702.
58.
TjeertesIBastiaansDVan GanzewinkelCZegersS. Neonatal anemia and hydrops fetalis after maternal mycophenolate mofetil use. J Perinatol.2007;27:62–64.
59.
VelinovMZellersN. The fetal mycophenolate mofetil syndrome. Clin Dysmorphol.2008;17:77–78.
60.
Dei MalatestaMRoccaBGentileT. A case of coloboma in a newborn to a woman taking mycophenolate mofetil in pregnancy after kidney transplantation. Transplant Proc.2009;41:1407–1409.
61.
HuangSChuehHShawS. Sonographic diagnosis of fetal malformations associated with mycophenolate mofetil exposure in utero. Am J Obstet Gynecol.2008;199(2):e6–e8.
CosciaLAConstantinescuSMoritzMJ. Report from the National Transplantation Pregnancy Registry (NTPR): Outcomes of pregnancy after transplantation. In: TerasakiPICeckaJM, eds. Clinical Transplants.Los Angeles, CA; Terasaki Foundation Laboratory2011:65–85.
65.
SibandaNBriggsJDDavisonJMJohnsonRJRudgeCJ. Pregnancy after organ transplantation: A report from the UK Transplant Pregnancy Registry. Transplantation.2007;83:1301–1307.
66.
KainzAHarabaczICowlrickI. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation.2000;70:1718–1721.
67.
ArmentiVConstantinescuSMoritzMDavisonJ. Pregnancy after transplantation. Transplant Rev.2008;22: 223–240.
68.
Munoz-Flores-ThiagarajanKDEasterlingTDavisCBondEF. Breast-feeding by a cyclosporine-treated mother. Obstet Gynecol.2001;97:816–818.
69.
GardinerSGearryRRobertsR. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations mother-infant pairs. Br J Clin Pharmocol.2006;62: 453–456.
70.
MorettiMVerjeeZItoS. Breast-feeding during maternal use of azathioprine. Ann Pharmacother.2006;40:2269–2272.
71.
ChristensenLDahlerupJNielsenM. Azathioprine treatment during lactation. Ailment Pharmacol Ther.2008;28: 1209–1213.
72.
NybergGHaljamäeUFrisenette-FichC. Breast-feeding during treatment with cyclosporine. Transplantation.1998;65: 253–255.
73.
ThiruYBatemanDCoulthardM. Successful breast-feeding while mother was taking cyclosporin. Br Med J.1997;23:463.
74.
MortonA. Cyclosporine and lactation. Nephrology.2011;16(2): 249–250.
75.
MadillJLevyGGreigP. Pregnancy and breast-feeding while receiving cyclosporine A. In: WilliamsBSandiford-GuttenbeilD, eds. Trends in Organ Transplantation.New York, NY: Springer Publishing Company; 1996:108–121.
76.
MorettiMSgroMJohnsonD. Cyclosporine excretion into breast milk. Transplantation.2003;75(12):2144–2146.
77.
GardinerSBeggE. Breastfeeding during tacrolimus therapy. Obstet Gynecol.2006;107:453–455.
78.
ItoS. Drug therapy for breastfeeding women. N Engl J Med.2000;343(2):118–126.
79.
JainAVenkataramananRFungJ. Pregnancy after liver transplantation under tacrolimus. Transplantation.1997;64: 559–565.
